Orthofix Medical says Medicare reimbursement for non‑invasive bone growth stimulators to revert to prior rates

Orthofix Medical expects average Medicare reimbursement for non‑invasive bone growth stimulators to return to pre‑May 18, 2026 rates.

Key Highlights:

• FDA reclassified non‑invasive bone growth stimulators from Class III to Class II on April 16, 2026, prompting CMS billing and fee schedule changes for HCPCS E0747, E0748 and E0760.
• On July 1, 2026, CMS withdrew those changes and directed that devices furnished on/after May 18, 2026 be processed and paid consistent with treatment prior to the reclassification.
• Orthofix currently expects average Medicare reimbursement for the three HCPCS codes to revert to rates in effect before May 18, 2026.
• Company cautions these are forward‑looking expectations subject to implementation, claim volumes, payer behavior and other risks that could affect actual results.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.